Shares of ImClone Systems ... Charts) fell nearly 8 percent after Jim Reddoch, analyst for Friedman, Billings, Ramsey, downgraded the stock to "market perform" and lowered his 12-month price ...

BOSTON (Reuters) - ImClone Systems Inc said on ... declined to comment. A $70 a share offer would represent a premium of 51 percent over ImClone's closing price of $46.44 on July 30, the day ...

Biotechnology company ImClone Systems Inc. said Wednesday that it ... a stake worth about $1 billion at the current share price. Under a contract running through 2018, if another company buys ...

ImClone Systems (IMCL) has rejected an unsolicited ... representing a premium of over 10% from the closing price on Tuesday of $63.65 per share. While numerous big pharma companies could be ...

Waksal, founder of biotech company ImClone Systems Inc., is due to be sentenced ... drove a run-up in ImClone’s stock price until late 2001, when the fortunes of Waksal and ImClone soured.

ImClone Systems’ share price surged by more than 18% on the Nasdaq Stock Exchange yesterday after clinical data showed that the firm’s oncology drug, Erbitux (cetuximab), used in combination with ...

BOSTON (MarketWatch) -- Eli Lilly & Co. said Monday that it plans to buy cancer-drug developer ImClone Systems for $70 a share, or about $6.5 billion, in an all-cash deal that is not subject to ...